126 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00704 | 10a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 28 µM |
| dbacp00705 | 10b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.4 µM |
| dbacp00706 | 10c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.6 µM |
| dbacp00707 | 11a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 5.2 µM |
| dbacp00708 | 11b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 19 µM |
| dbacp00709 | 11c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.2 µM |
| dbacp00710 | 12a | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 6.1 µM |
| dbacp00711 | 12b | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 27 µM |
| dbacp00712 | 12c | NA | Synthetic b2,2-amino acid derivatives | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14 µM |
| dbacp00722 | 5a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10.6 µM |
| dbacp00723 | 5b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.1 µM |
| dbacp00724 | 5c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.1 µM |
| dbacp00727 | 6a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 14.4 µM |
| dbacp00728 | 6b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11.0 µM |
| dbacp00729 | 6c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 4.3 µM |
| dbacp00730 | 7a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >63 µM |
| dbacp00731 | 7b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >78 µM |
| dbacp00732 | 7c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 79 µM |
| dbacp00733 | 8a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 136 µM |
| dbacp00734 | 8b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : >254 µM |
| dbacp00735 | 8c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 107 µM |
| dbacp00736 | 9a | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 31 µM |
| dbacp00737 | 9b | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 2.3 µM |
| dbacp00738 | 9c | NA | Not found | Induction of apoptosis; Disruption of cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.1 µM |
| dbacp00745 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 93 µM |
| dbacp00746 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 39 µM |
| dbacp00747 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 37 µM |
| dbacp00748 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 36 µM |
| dbacp00749 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 25 µM |
| dbacp00758 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 38 µM |
| dbacp00759 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 43 µM |
| dbacp00760 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 43 µM |
| dbacp00761 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 45 µM |
| dbacp00762 | 9S1R | RRRRRWCMNW | Nullomer derived anticancer peptides (NulloPs) | Cell membrane disintegration; Apoptosis | MTT/MTS assay | HUT-102 | Lymphoma cancer | IC50 : 36 µM |
| dbacp00983 | Adenoregulin | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | South American frog, Giant leaf frog | Cell membrane disintegration | LDH leakage assay | Raji | Lymphoma cancer | GI50 : 2.57 ± 0.75 µM |
| dbacp01213 | ATP-binding cassette sub-family C member 3 | MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHCRGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLATLLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFALVLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDLWSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFLKALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCSMMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRFMDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQMKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWMCSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLnMLPQLISNLTQASVSLKRIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVVGPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRYQQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSAVDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQRNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQKQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFWDYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGILQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVDEVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLESVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVEFVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERVKEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVGIVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTLRMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARALLRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGVVAEFDSPANLIAARGIFYGMARDAGLA | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2μM |
| dbacp01217 | ATP-binding cassette sub-family C member 5 | MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAEGLSLDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMTFSWLSSLARVAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDAASLRRVVWIFCRTRLILSIVCLMITQLAGFSGPAFMVKHLLEYTQATESNLQYSLLLVLGLLLTEIVRSWSLALTWALNYRTGVRLRGAILTMAFKKILKLKNIKEKSLGELINICSNDGQRMFEAAAVGSLLAGGPVVAILGMIYNVIILGPTGFLGSAVFILFYPAMMFASRLTAYFRRKCVAATDERVQKMNEVLTYIKFIKMYAWVKAFSQSVQKIREEERRILEKAGYFQSITVGVAPIVVVIASVVTFSVHMTLGFDLTAAQAFTVVTVFNSMTFALKVTPFSVKSLSEASVAVDRFKSLFLMEEVHMIKNKPASPHIKIEMKNATLAWDSSHSSIQNSPKLTPKMKKDKRASRGKKEKVRQLQRTEHQAVLAEQKGHLLLDSDERPSPEEEEGKHIHLGHLRLQRTLHSIDLEIQEGKLVGICGSVGSGKTSLISAILGQMTLLEGSIAISGTFAYVAQQAWILNATLRDNILFGKEYDEERYNSVLNSCCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDAHVGNHIFNSAIRKHLKSKTVLFVTHQLQYLVDCDEVIFMKEGCITERGTHEELMNLNGDYATIFNNLLLGETPPVEINSKKETSGSQKKSQDKGPKTGSVKKEKAVKPEEGQLVQLEEKGQGSVPWSVYGVYIQAAGGPLAFLVIMALFMLNVGSTAFSTWWLSYWIKQGSGNTTVTRGNETSVSDSMKDNPHMQYYASIYALSMAVMLILKAIRGVVFVKGTLRASSRLHDELFRRILRSPMKFFDTTPTGRILNRFSKDMDEVDVRLPFQAEMFIQNVILVFFCVGMIAGVFPWFLVAVGPLVILFSVLHIVSRVLIRELKRLDNITQSPFLSHITSSIQGLATIHAYNKGQEFLHRYQELLDDNQAPFFLFTCAMRWLAVRLDLISIALITTTGLMIVLMHGQIPPAYAGLAISYAVQLTGLFQFTVRLASETEARFTSVERINHYIKTLSLEAPARIKNKAPSPDWPQEGEVTFENAEMRYRENLPLVLKKVSFTIKPKEKIGIVGRTGSGKSSLGMALFRLVELSGGCIKIDGVRISDIGLADLRSKLSIIPQEPVLFSGTVRSNLDPFNQYTEDQIWDALERTHMKECIAQLPLKLESEVMENGDNFSVGERQLLCIARALLRHCKILILDEATAAMDTETDLLIQETIREAFADCTMLTIAHRLHTVLGSDRIMVLAQGQVVEFDTPSVLLSNDSSRFYAMFAAAENKVAVKG | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2 μM |
| dbacp01440 | BAA-1 | NA | Bovine lactoferrin (Lf-B) | Destabilizing the cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8.1 µg/ml |
| dbacp01441 | BAA-2 | NA | Bovine lactoferrin (Lf-B) | Apoptosis inducing | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.8 µg/ml |
| dbacp01607 | Bim | EIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | EL4 | Mouse T cell lymphoma | Not found |
| dbacp01962 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | BJAB | B-cell lymphoma | LD50 : 10 – 15 μg/ml |
| dbacp01963 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | BJAB | B-cell lymphoma | LD50 : 20 – 25 μg/ml |
| dbacp01964 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | BJAB | B-cell lymphoma | LD50 : 30 – 40 μg/ml |
| dbacp01981 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | BJAB | B-cell lymphoma | LD50 : 30 – 40 µg/ml |
| dbacp01987 | Buforin 2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 90-95 µg/ml |
| dbacp02105 | Buforin2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 5% Cytotoxicity at 0.5 µg/ml |
| dbacp02145 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 ±2 µMol/L |
| dbacp02146 | C1 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 22 ±5 µMol/L |
| dbacp02148 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 7.9 ± 0.3 µMol/L |
| dbacp02149 | C2 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 1.71 ± 0.6 µMol/L |
| dbacp02150 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 15 ± 2 µMol/L |
| dbacp02151 | C3 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 92 ± 2 µMol/L |
| dbacp02152 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 12.6 ± 0.6 µMol/L |
| dbacp02153 | C4 | KWβ2,2KK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 99 ± 15 µMol/L |
| dbacp02154 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 11 ± 2 µMol/L |
| dbacp02155 | C5 | KKWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 23 ± 3 µMol/L |
| dbacp02156 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8 ± 1 µMol/L |
| dbacp02157 | C6 | KWβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 26 ± 2 µMol/L |
| dbacp02158 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 16 ± 5 µMol/L |
| dbacp02159 | C7 | KKβ2,2WKK | Synthetic construct | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 157 ± 30 µMol/L |
| dbacp02223 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 20 ± 2 µMol/L |
| dbacp02224 | C8 | KWβ2,2KK | Not found | Membrane disruptive mode of action | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 226 ± 21 µMol/L |
| dbacp02311 | Cathelicidin antimicrobial peptide | MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2μM |
| dbacp02484 | Chrysophsin-1 | FFGWLIKGAIHAGKAIHGLI | The pyloric caeca and gills; Red sea bream | Disruption of cancer cell membranes; Apoptosis | MTS assay, Lactate dehydrogenase (LDH) detection assay | U937 | Histiocytic lymphoma | MIC : 7 µg/ml |
| dbacp02487 | Citropin 1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-938 | Lymphoma cancer | IC50 :40 µg/ml |
| dbacp02512 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02513 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02646 | Demegen P-113 | AKRHHGYKRKFH | Thrush | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-939 | Lymphoma cancer | IC50 : 85-90 µg/ml |
| dbacp02647 | Demegen P-113 | AKRHHGYKRKFH | Amphibian skin peptide | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 15% Cytotoxicity at 0.5 µg/ml |
| dbacp02648 | DepA | MYSSSDVASRRISAADKFGPHHAFPHREALSIARQLLWRAEASPDRLAYASADPVKNIALSYAGLCERASGIAARLAQATETGDRVMLVYQEPLDFLPAFFGCCLAGVIPVPVAPRHGRDTMLAIAEDCGAVIALTAEARDALPGLRWMRTDETEGAAPFLRAAGEGSPVLLQYTSGSTRTPQGVVVTQTGLWATIEDLDRGAMHDADSVMISWLPYFHDMGLVYGILTPLQCGFPAYLMAPEKFVAQPMSWLRAIEARRGTHTAAPNFAYALCADRAADLAPGTDLSSLRYALNGAEPVRCDTVRRFEAAFAPFGLKPSVVAPGYGLAEATLKVTAGRCGEGTRGVRFGRDALARGRVSPEADGVELAACGSSLIDTRVRIVNPDTREPCEADVVGEIWVSGSTVADSYWRRPEESREIFGARLADDNGVWLRTGDLGFLYDGDLFVTSRLKDLIIVGGRNFYSHDLEDTVSACHPSIRMGRVFAAAVDGEEGEGVLIGAEVRGGCEEADAREILPVIRAALAREHGVAPARVALLRRGSILRTSSGKTRRSATRDALLRGELSIIADDAADMSDDAILAEISSFVPGAAATSDARLIDLGLDSLSAARLAAMARARHGVELSFATLFALSAEQLRREIVAARARHDGSAAPVSVRGYAAGEPFELSEMQQAYWIGQQGGVPLGSVSPHIRVDFEIDAARAPELGRRLASLVARHPSLRMTVGADGRGVFDALAYDPLLPPQDLRGLDAAEAAERLEATRASLAERDGPPVVAAVTRLTDSTAILHMRLGLLAGDLRSFLQLMAELARGAAGDVPAQLITPMTPATPTGEQREAWLRRVEAIAPAPELPMKMALADVAEPRFAGRRRELPAALSAALAARAQGLGVTLTSLCIAAFADTLRLWTAAHAFTLNVTCNTRAEQAGQAIGDYTSNALLSLSERHESFAAFAREVQRQVWADLDAPWCSGVSILRELSRRNGAPVLMPVVLTSLLSGDPADDLSILDGIGRVVDMANPTPQVSLHAVLGRRGDRLLVMWEFVAQLFPEGMIDAMFDAFLGALETMATEAAALERPTVARLAPEQAARREAVNATEAERAPRRLETPIIRQALTTPEAVAVRQGAATLSYGELLRQAEDIAGALRQSGVARGDVVAAIVAPGPRAVAALLGIVMAGAVYLSIEPSWPAARIEELLGEAGARHAVVSEGGWTLPVQALRLDLPLPPGDAGPAPDLEAGDAAYVIFTSGSTGRPKGVLIAHEAAANTIDDINERFAVGPADRTLCVSSLAFDLSVYDIFGLLAVGGEVVFPERARDPDAMAQALCDGRITIWNSVPAVLELLLDVAAPRSPDLRLALLSGDWIAPGLAGRLRDAFPALRPISLGGATEVSIWSVVHPIAPEDAALASIPYGRPLSNQQCFVRAPDGRERPDGVVGELLLGGRGLALAYLGNEAETQRRFFIDAEGRRLYRTGDLARWQPDGELELLGRMDGQVKVQGYRIELGEIEAAAMRAGCLARAVASVVRRNNATAIQLHVVARPDYDGDIVAAVRAKLVLHLPAYMQPHHVTVLDALPLTANGKVDRARLAALAAPAPASAKPAATARRDDSLEATMLAAFAEVVGVEIDPQQGFFDAGATSMHVVRLRALLASRGVVVPPLVDFFSLATIRALAERADSGDADLSPMIDVDGARAYRQRVRARKEAL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02649 | DepD | MTMARLMTDLADAGVTLRRRGDQLQVQAPQGALDAALVARLREAKEELLRVLDDEGARAAPLAPAQPGEAGDAAALSPGQARLVAATRLGDPAMYNEQAAIELADAVDAEAVARAFAALARRHDILRTVFSDGEPVRQTVLPEPIVTLQAWTVDGDDALRARAADLARLPFAAGAPMWRVDLFSTPERAAVLVLTIHHAIFDRWSMSVLIRDFSAYLALPDAAEAPASGLSYRDYSAWQRRWMASPDYAAQLDAWVDDLAEVDEVPAIRGDRPRPPAMSGRGGTERFEIPADCMDAAAAFSRSRNTTLFTTLFSAFALLQHRYTGEARALTLTPAANRPFQAAEEIAGYFVNLVALATEVGEGDSFGALVDRARDASARAFARQGVPLDAIVERLRARGGPRHEQFAQTVFAFQNVRLPAVRTASGAAVPFDLDSPFARFDLYLSIEGDERGTFAVWQYNTDLYEAATIRQLGEHYLALLRAALASPDADARALPILSAEEEARLRGWGRHELPYRADAAIDRLFRERAADHPGRVALEQGGVRWTYAELDQWSDRAAGALRAAGVEAGAVVGVAGERSPRLLAAFLAVLKAGAAYLPLDPTYPAARLRAMTADAAPALMIIADGLDAGWLGDYAGPVLSLADCEAGVARPLQSEARPAEAESLAYVMYTSGSTGQPKGVAVPHRAVARLATGGGYARLDASTVMLQQSPLGFDASTFEIWGCWLNGGRLVVAEPGMPFLDAASRDGVTTMWLTADLFRMAVEEEPAALGGLRELLTGGDALPVASCRAFLEACPGVALINGYGPTENTTFTCSHRVTAGDARRGSIPIGRPIGNTEVRVVDAGGRLVPVGVPGELWAGGDGLALGYLGRADLTAERFVAAPPPDGGRWYRTGDRVRWRRDGVLEFLGRIDEQIKLRGYRIELGEIEATLGHYPGLSGCAVALRRSAADEKQLVGYLVARPDSGEAADSAAVQAWLEARLPGYMVPRVWVWLDALPQSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAEECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPLRLPLSGELSGDLKRVKERMRSVPDGGLAYHALRYGGRGSALGGHARTVCFNYLGQWRLEEGGEPRSTWLGEPPGGTRGAGMTRRYGLDVVAQVHEGRLRVDWLYSAARQREDAIKALAEGFRAELDAVLAHCQSPESGGLTPSDLPLAHLDQSEIDAIEREHPRLEALYGLTPLQQGILFHSIADDGAPLYVEQLHWKMSGAFDAERFRQAWFDVAAAHAALRTTFRWRGLKSAVQIVHPRLDPDWETLDWGDVSADACASRFAALCELHRERGFDLERGPLLRGTLVREPGDAWRFLWSYHHAVVDGWSVPLILKQVLGRYAELGAGEAAPLPGSRFLPFVNWLAARDAREQAEYWKQVLEGIEEPTPIGFASPARGPQAQGQGRRAFVFDAALREQVDRAARRAGVTRASLLTGAWALTLGYAGGGRDVVFGTTLSGRPATLPGVERMVGLFINTVPVRVGMDDDASVSQWLRQLHEQQSERARLGAASLTDIQRWAGYEGGELLSSLFVVENYPVDRTLARGDAGFDVSEFAAAETRTNYPLVGQLIPGEETVLYVDFDASRYDEESIGRLGASFMHLLSQLAAQPDARLGDLTLVDDDEARRLIHDWNATPPVGEGYLLHASIERHAELTPLAPAIIGVDEAMNYRELADETLRTARAVAAAGAKREPVAVLLPRSARAVAAYSGVMRAGCAYVPADPAMPPGRLRDLLATVGYVLTTREHLPMLDGVAARAILIDETPPADVALPDAAPDDLAYVMFTSGSTGKPKGVMITHRAASLTIEVFLRRYEIGASDRLMCVSAAGFDLSVFDFFGAFAAGAAVLLAPESSTIAPAVWLELMTREGATVWESVPAVMELLLLECRQSGRALPPSLKLAMLSGDRVPVGLPAQIRAAATSDPEVLALGGATEGAIWSCWYDTRELASDAAFVPYGRHLPGQRLYVLSSSLQAVPVGVPGDLWIAGAGVALGYLGQPDLTAYRFVDNPFVPGERMYRTGDRARVLADGNLEFLGRVDDQVKIGGFRIEIGEIEAALAAAPGVERGVASVVERDGRRIIAGYVLLLPGASLDLAAVRDALARRLPPYMLPASIMALDSLPLSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAKECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPLRLPLSGELSGDLKRVKERMRSVPDGGLAYHALRYGGRGSELGGHARTVCFNYLGQWRLEEGGEPRSTWLGEPPGGTRGAGMTRRYGLDVVAQVHEGRLRVDWLYSAARQREDAIKALAEGFRAELDAVLAHCQSPESGGLTPSDLPLAHLDQNDIDEVLQLLNEQL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02650 | DepE | MNQTLSNTAQQARSKVETMLPLTPTQQGLLFHTLKAPESGVYYEQVACSFHAALNAADYRRALEAVVARHGVLRTGFLWDGPSKPVQVVFRDVALPWVEEDWRAFDQEEQQRRLAAYRDADRRPGFHLSRAPLMRCALFRTGEERYEFVWSYHHLLLDGWSVQIVLGEALAFYDAYRRSAVPAMPPPQPYSAFLRWLDEQDGAEAEAFWRARLGDVRSATPLPFADDARPDRAPGHGLIERELDARTSEGLQRLARECELTQSTVIQAAWALLLARASGRDDVVFGTTVSGRPAALRGVEQMVGLFVNALPTRASVDLELRLGDWLRRLHRQHVDAEAYAYTPLHAIPGWSGVAPGAPLFESLVVFENYPARADAKRYREQLGVSDVEVVEQTNYPLTVVAIPGERLSLRLHFDRQRISAASAERVVEMLTGVLGQFERGGPALSVARVSLLGDEAGGALAARWNAAARRADDAERQCLHRRFEAQARSRPDAVALKCDGETLTYAELDRRANRLAWRLDAAGVRGNAPVALAFGRGMDSVVAILAVLKAGAFYVPLDLDHPSERLAWMLDDIGAGALICGEEARDRFGDFGGVLIGMGDAAAPGEREDAPPPRDTSPADLCYVIYTSGSTGQPKGVCVEHRNADHLFAATRRSYGIGPSDVWTLFHSYAFDFSVWEIWGALLHGGRLEIVPYRCSRTPDEFLALLEREGVTMLSQTPSAFKQLLRALDDARRPLPAGLRYVFFGGEATIPSQFAACLNDAGGVALVNLYGITETTVHVTERVLGPGDAQSSRSPVGRPLPGYRVYLLDAAGHPVPPGVPGEIHVGGEGVARGYHNRPELDRERFIADPFLPGERLYRSGDLGRFDARGELDYLGRIDDQVKIRGFRIELGEVEATLARHPDVAAAAVMVDDATIDGHAQLAGFVVARGSARVSGSALRDWLAQRLPPHAVPARVVEMDAIPLTSNGKLDRRRLAGALAADADAARPRIAPRNTVEQALVGVFESVLKRSPIGVTDNFFELGGDSILSIQILSAAHKVNIDFSLDDLMRSLTIERLAPRVRQAGSAPPTASAPPLDAVHEDAYPLSAMQMAMLANEMRHGQDSAYHNVNGQRLALPFDAAALEAALRGAFERHPALRTAFDLAADEEPLQYVHRQVPLPLTVSDWRGLDPERQDERIRDWREAERRRRFDVERPPLIRFAVHRLSEKAMHIGVTKHHAILDGWSFNLLLSELISDYSARLAGRPLTLAAPASRFRDFVEREREAARSESLRDWWRARLQSLPVTRLAREPGGDAEPVDVPISAAQSAGLEALAASAGASVKSVLLTAHLLALSRIAGASSVTSGVVFNGRSEGVDGDRVLGLFLNSLPLGFDFPAGAFDAVALVRAVQSAELEVFSRRRYPLIELHRQAGTVFDALFNFTHFRALEEAVRDIEVSDGYASDMTNVPLVVQSSFDGRQRALRITLVPSRGYFSMATVNRFAALYADALRTLLGEPAAEGAGAVGAIRADGGERRSGASTAATPAAAGRAAAARPSGAALRRELRALWAAVLKREPPSDDSDFVALGGDSLLMLRICSRAGRAFGLNSAVVARLLTAQTVAEQARVIETDGAGEDGARVGSLVALSAQGDAPPLFFAPGAGGHVPYLRALAAELPNAFSVWGMTLPGDAGSVEAMATALIADIRRAQPYGPYRLGGHSFGGWVAFEVARQLAGQGEAVDWVAVVDSLPPGPAAQSRKQDWQGGRWVAEIGNSFARLADAELAFDEGEFDALDDARRVEHLRERLVEAGAVPEALGLPEFAARVRAFIAHSLTDYTPATPYAGALHVIVAADGDGEALISGWRQAASGAATAVRLAGDHIGIMRRPFVNGLAAALRAAEAAARRSVSVKQTEEEQ | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp02802 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | DB | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02803 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | HT | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02804 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | RL | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02806 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | DB | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02807 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | HT | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02808 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | RL | Lymphoma cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp03407 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2μM |
| dbacp03736 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | U-266 | Lymphoma cancer | IC50 : 55 µM |
| dbacp03739 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Raji | Lymphoma cancer | IC50 : 13 µM |
| dbacp03740 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 µM |
| dbacp04487 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04492 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04505 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 16 µg/ml |
| dbacp04510 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 20 µg/ml |
| dbacp04515 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 17 µg/ml |
| dbacp04520 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 23 µg/ml |
| dbacp04531 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 19 µg/ml |
| dbacp04536 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 25 µg/ml |
| dbacp04796 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04797 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 60% cell viability at 50 µM |
| dbacp04802 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04803 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 60% cell viability at 50 µM |
| dbacp04808 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04809 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 40% cell viability at 50 µM |
| dbacp04814 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04815 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 40% cell viability at 50 µM |
| dbacp04866 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | NK-lysin | Cell membrane disintegration | PI-uptake assay | U-937 | Lymphoma cancer | LD50 : 30 µM |
| dbacp05012 | Omiganan MBI-226 | ILRWPWWPWRRK | Cattle neutrophils | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 80 - 85 µg/ml |
| dbacp05013 | Omiganan MBI-226 | ILRWPWWPWRRK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 27% Cytotoxicity at 0.5 µg/ml |
| dbacp05398 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 ± SD : 5.2 ± 2.2 μM |
| dbacp05487 | Pexiganan acetate | GIGKFLKKAKKFGKAFVKILKK | Engineered | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |
| dbacp05488 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-941 | Lymphoma cancer | IC50 : 20-30 µg/ml |
| dbacp05489 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |
| dbacp05649 | Protegrin 1 | RGGRLCYCRRRFCVCVGR | Alpha helical peptide without cysteines | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-942 | Lymphoma cancer | IC50 : 30-40 µg/ml |
| dbacp05650 | Protegrin 1 | RGGRLCYCRRRFCVCVGR | Alpha helical peptide without cysteines | Not specified | MTT/MTS assay | U-937 | Lymphoma cancer | 61% Cytotoxicity at 0.5 µg/ml |
| dbacp05652 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | Daudi lymphoma cells | Lymphoma | IC50 : 5.2 ± 2.2 μM |
| dbacp05781 | Putative nonribosomal peptide synthetase P4-B4-NRPS | DAWRFLWSYHHAVVDGWSVPLILKQVLGRYAELGAGEAAPLPGSRFLPFVNWLAARDAREQAEYWKQVLEGIEEPTPIGFASPARGPQAQGQGRRAFVFDAALREQVDRAARRAGVTRASLLTGAWALTLGYAGGGRDVVFGTTLSGRPATLPGVERMVGLFINTVPVRVGMDDDASVSQWLRQLHEQQSERARLGAASLTDIQRWAGYEGGELLSSLFVVENYPVDRTLARGDAGFDVSEFAAAETRTNYPLVGQLIPGEETVLYVDFDASRYDEESIGRLGASFMHLLSQLAAQPDARLGDLTLVDDDEARRLIHDWNATPPVGEGYLLHASIERHAELTPLAPAIIGVDEAMNYRELADETLRTARAVAAAGAKREPVAVLLPRSARAVAAYSGVMRAGCAYVPADPAMPPGRLRDLLATVGYVLTTREHLPMLDGVAARAILIDETPPADVALPDAAPDDLAYVMFTSGSTGKPKGVMITHRAASLTIEVFLRRYEIGASDRLMCVSAAGFDLSVFDFFGAFAAGAAVLLAPESSTIAPAVWLELMTREGATVWESVPAVMELLLLECRQSGRALPPSLKLAMLSGDRVPVGLPAQIRAAATSDPEVLALGGATEGAIWSCWYDTRELASDAAFVPYGRHLPGQRLYVLSSSLQAVPVGVPGDLWIAGAGVALGYLGQPDLTAYRFVDNPFVPGERMYRTGDRARVLADGNLEFLGRVDDQVKIGGFRIEIGEIEAALAAAPGVERGVASVVERDGRRIIAGYVLLLPGASLDLAAVRDALARRLPPYMLPASIMALDSLPLSANGKVDRKRLPDPVVETGAAAAETEAEAALVEIWQGLLGLERVGVRDNFFALGGDSILSIQMASRAAERGLRLSPQQVFRYPTIAELAAEGCAAEEAGAQAEQGEVVGEVRPGPIQAWYLDWPGTDWEQFNQGAYLGLDGVVDAESLIGALQAVAQRHDALRIGWRRDGERWIQASGAGEPVEVKAVDLRGLADAEAALERDAAALQSSLRLGGASLWAARLYRLDEGWRLLWLAHHASVDGVSWRILLEDLWRAYAALSRGEAAAWPAKTVSYQAWSQRLWEWAETLPDSTLSYWREMDAPGMPLPGFNAAEDTVAAESRVSLQWEPETTERWLRQAGEAYRMRPEELLVTALARALRQWTGAKECVLDLEGHGRDGLAGVDVSRTVGWFTSLYPL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp05782 | Putative nonribosomal peptide synthetase P4-G7-NRPS | MTMARLMTDLADAGVTLRRRGDQLQVQAPQGALDAALVARLREAKEELLRVLDDEGARAAPLAPAQPGEAGDAAALSPGQARLVAATRLGDPAMYNEQAAIELADAVDAEAVARAFAALARRHDILRTVFSDGEPVRQTVLPEPIVTLQAWTVDGDDALRARAADLARLPFAAGAPMWRVDLFSTPERAAVLVLTIHHAIFDRWSMSVLIRDFSAYLALPDAAEAPASGLSYRDYSAWQRRWMASPDYAAQLDAWVDDLAEVDEVPAIRGDRPRPPAMSGRGGTERFEIPADCMDAAAAFSRSRNTTLFTTLFSAFALLQHRYTGEARALTLTPAANRPFQAAEEIAGYFVNLVALATEVGEGDSFGALVDRARDASARAFARQGVPLDAIVERLRARGGPRHEQFAQTVFAFQNVRLPAVRTASGAAVPFDLDSPFARFDLYLSIEGDERGTFAVWQYNTDLYEAATIRQLGEHYLALLRAALASPDADARALPILSAEEEARLRGWGRHELPYRADAAIDRLFRERAADHPGRVALEQGGVRWTYAELDQWSDRAAGALRAAGVEAGAVVGVAGERSPRLLAAFLAVLKAGAAYLPLDPTYPAARLRAMTADAAPALMIIADGLDAGWLGDYAGPVLSLADCEAGVARPLQSEARPAEAESL | Gram-negative bacillus | Inducing apoptosis | GFP assay | NIH 3T3 | Cutaneous T-cell lymphoma | Not found |
| dbacp06200 | TAT-Bim (145-165) | RKKRRQ(orn)RRREIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | EL4 | Mouse T-cell lymphoma | Not found |
| dbacp06226 | Temporin A | FLPLIGRVLSGIL | Common frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-943 | Lymphoma cancer | IC50 : 80-90 µg/ml |
| dbacp06227 | Temporin A | FLPLIGRVLSGIL | Common frog | Cell membrane disintegration | MTT/MTS assay | U-937 | Lymphoma cancer | 15% cytotoxicity at 0.5 µg/ml |
| dbacp06228 | Temporin A | FLPLIGRVLSGIL | European common frog | Cell membrane disintegration | MTT/MTS assay | U-937 | Lymphoma cancer | 15% cytotoxicity at 0.5 µg/ml |
| dbacp06230 | Temporin L | FVQWFSKFLGRIL | European common frog | Cell membrane disintegration | MTT/MTS assay | U-938 | Lymphoma cancer | 15% cytotoxicity at 0.5 µg/ml |
| dbacp06557 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 123 µg/ml |
| dbacp06562 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 72 µg/ml |
| dbacp06573 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 97 µg/ml |
| dbacp06578 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | Raji | Lymphoma cancer | IC50 : 64 µg/ml |
| dbacp07345 | HMP-S7 | SFIPRAKSTWLNNIKLL | Human Milk | Membrane penetration, cytoplasmic leakage | Trypan blue assay | Raji | Lymphoma Cancer | IC50 = 89 ± 24 µM |
| dbacp08180 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | RL | Lymphoma Cancer | Not Available |
| dbacp08383 | IDP-LS13 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | U266 | Lymphoma Cancer | EC50 ~ 10 μM |
| dbacp08385 | IDP-LS15 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | U266 | Lymphoma Cancer | EC50 ~ 8 μM |
| dbacp08387 | IDP-LS16 | APKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | U266 | Lymphoma Cancer | EC50 ~ 10 μM |
| dbacp08389 | IDP-LS17 | APKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | U266 | Lymphoma Cancer | EC50 ~ 16 μM |
| dbacp08437 | Balixafortide | ACSAp(Dab)RYCYQKpPYH | Synthetic | Not Available | HUVEC sprouting | Namalwa | Lymphoma | IC50< 10 nM |